Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

P&G's Intrinsa Priority Review Puts Approval Timeline At Early 2005

This article was originally published in The Pink Sheet Daily

Executive Summary

NDA for testosterone patch to treat reduced sexual desire in surgically menopausal women was submitted in early summer. First female sexual dysfunction agent filed at FDA is "next major opportunity" for P&G's pharmaceutical business, CFO Daley tells Banc of America Securities conference.

You may also be interested in...



Vivus Evamist Menopause Spray To Start Phase III Under Special Protocol Assessment

Firm will conduct single 12-week trial for treatment of moderate to severe vasomotor symptoms with the transdermal estradiol spray. Evamist would be the first estradiol topical spray formulation, Vivus says.

Vivus Evamist Menopause Spray To Start Phase III Under Special Protocol Assessment

Firm will conduct single 12-week trial for treatment of moderate to severe vasomotor symptoms with the transdermal estradiol spray. Evamist would be the first estradiol topical spray formulation, Vivus says.

P&G’s Intrinsa For Female Sexual Dysfunction To Get Cmte. Review Dec. 2

If recommended by FDA’s Reproductive Health Drugs Advisory Committee, Intrinsa would be on a path for approval in December or January. The testosterone patch could be the first treatment for female sexual dysfunction.

Topics

UsernamePublicRestriction

Register

MT142539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel